ESMO 2024 – Dr Meredith McKean

In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.

The conversation explores the five-year survival data presented at the congress on Libtayo, a PD-1 inhibitor, as a first-line monotherapy in advanced non-small cell lung cancer (NSCLC), as well as the potential for combination therapies in oncology, the melanoma space more generally, and the importance of collaboration when it comes to cancer care transformation.

Tune into the video below, and be sure to catch up on other ESMO 2024 discussions with EVERSANA, Regeneron, Johnson & Johnson, AbbVie, and QuicDNA.